Commercial street

I-Mab Reports Third Quarter 2024 Results

I-Mab Biopharma

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 2 3 4 5 6 7 8 Next Tail

10 Items Per Page (Page 5 / 79) Total 784 Items

©Copyright 2009-2020 Yahoo Perspective   cryydr@163.com   Contact Us   SiteMap